Digital breast tomosynthesis (DBT) is a new modality that aids in breast cancer detection. It is a pseudo-three-dimensional digital mammography imaging system that produces a series of 1-mm-slice images with multiple very low-dose X-ray projections to reveal the inner architecture of the breast after eliminating interference from overlapping breast tissue. This review article provides an overview of the current and potential use of DBT. The illustrations and discussion are based on our experience with the Selenia Dimensions (Hologic, USA) DBT system approved by the US Food and Drug Administration.
Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.